Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506), based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a Phase II clinical study for its antibody-drug conjugate (ADC) BL-M07D1 in patients with advanced solid tumors. The trial will evaluate BL-M07D1 in combination with a domestically marketed anti-PD-1/PD-L1 therapy, with or without chemotherapy.
Additionally, a separate Phase II study will investigate the efficacy of BL-M07D1 in breast cancer patients, in combination with pertuzumab, also with or without chemotherapy. BL-M07D1 is being developed as a treatment option for breast cancer, gastric cancer, and other solid tumors, marking a significant step forward in Biokin’s oncology pipeline.- Flcube.com
